Susquehanna International Group, LLP Viking Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$47.39 - $80.2 $47.2 Million - $79.8 Million	-995,300 Reduced 31.76%	2,138,600 $113 Million
Q1 2024 May 07, 2024	BUY	$17.4 - $94.5 $34.5 Million - $188 Million	1,984,500 Added 172.66%	3,133,900 $257 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $2.69 Million - $5.73 Million	291,600 Added 33.99%	1,149,400 $21.4 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $9.68 Million - $14.2 Million	-886,100 Reduced 50.81%	857,800 $9.5 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $14.1 Million - $23.6 Million	950,100 Added 119.69%	1,743,900 $28.3 Million
Q1 2023 May 16, 2023	BUY	$8.08 - $17.33 $4.04 Million - $8.66 Million	499,900 Added 170.09%	793,800 $13.2 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $600,304 - $2.07 Million	220,700 Added 301.5%	293,900 $2.76 Million
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $25,500 - $38,900	10,000 Added 15.82%	73,200 $199,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $13,504 - $20,160	6,400 Added 11.27%	63,200 $183,000
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $179,700 - $292,312	-59,900 Reduced 51.33%	56,800 $170,000
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $1.07 Million - $1.57 Million	-233,200 Reduced 66.65%	116,700 $537,000
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $859,878 - $1.08 Million	154,100 Added 78.7%	349,900 $2.2 Million
Q2 2021 Aug 11, 2021	SELL	$5.19 - $6.73 $880,743 - $1.14 Million	-169,700 Reduced 46.43%	195,800 $1.17 Million
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $1.36 Million - $2.29 Million	237,200 Added 184.88%	365,500 $2.31 Million
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $865,490 - $1.1 Million	-163,300 Reduced 56.0%	128,300 $722,000
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $327,756 - $463,891	-57,200 Reduced 16.4%	291,600 $1.7 Million
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $910,454 - $1.69 Million	209,300 Added 150.04%	348,800 $2.52 Million
Q1 2020 May 15, 2020	SELL	$3.45 - $7.95 $1.76 Million - $4.06 Million	-510,100 Reduced 78.53%	139,500 $653,000
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $1.48 Million - $2.02 Million	-231,600 Reduced 26.28%	649,600 $5.21 Million
Q3 2019 Nov 14, 2019	SELL	$6.55 - $8.6 $3.19 Million - $4.19 Million	-486,900 Reduced 35.59%	881,200 $6.06 Million
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $173,342 - $240,238	22,600 Added 1.68%	1,368,100 $11.4 Million
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $9.35 Million - $12.3 Million	1,234,100 Added 1107.81%	1,345,500 $13.4 Million
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $2 Million - $4.52 Million	-279,000 Reduced 71.47%	111,400 $852,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $579,090 - $1.17 Million	59,700 Added 18.05%	390,400 $6.8 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $730,992 - $2.4 Million	188,400 Added 132.4%	330,700 $3.14 Million
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $584,853 - $986,139	142,300 New	142,300 $622,000

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account